{"version":"1.0","license":"CC BY 4.0","attribution":"AmericanPeptide.com","documentation":"https://www.americanpeptide.com/developers","generated":"2026-06-01T01:26:22.914Z","filters":{"category":null,"area":"weight-loss","fda":true,"q":null},"categories":[{"id":"metabolic","label":"Metabolic"},{"id":"growth-hormone","label":"Growth Hormone"},{"id":"healing-repair","label":"Healing & Repair"},{"id":"cognitive","label":"Cognitive"},{"id":"longevity","label":"Longevity"},{"id":"cosmetic","label":"Cosmetic"},{"id":"reproductive","label":"Reproductive"},{"id":"immune","label":"Immune"},{"id":"mitochondrial","label":"Mitochondrial"}],"researchAreas":[{"slug":"weight-loss","label":"Weight Loss & Metabolic Health"},{"slug":"wound-healing","label":"Wound Healing & Tissue Repair"},{"slug":"cognition-neuroprotection","label":"Cognition & Neuroprotection"},{"slug":"anxiety-mood","label":"Anxiety, Mood & Stress"},{"slug":"sleep-circadian","label":"Sleep & Circadian Rhythm"},{"slug":"longevity-aging","label":"Longevity & Aging"},{"slug":"growth-hormone-axis","label":"Growth Hormone & Body Composition"},{"slug":"skin-hair","label":"Skin & Hair"},{"slug":"sexual-reproductive","label":"Sexual & Reproductive Health"},{"slug":"immune-inflammation","label":"Immune & Inflammation"},{"slug":"mitochondrial","label":"Mitochondrial & Bioenergetics"}],"count":3,"peptides":[{"slug":"semaglutide","name":"Semaglutide","aliases":["Ozempic","Wegovy","Rybelsus"],"categories":["metabolic"],"categoryLabels":["Metabolic"],"researchAreas":["Type 2 diabetes","Obesity","MASH","Cardiovascular risk reduction"],"researchAreaGuides":[{"slug":"weight-loss","label":"Weight Loss & Metabolic Health","url":"https://www.americanpeptide.com/research-areas/weight-loss"}],"shortDescription":"Long-acting GLP-1 receptor agonist for glycemic control and weight management.","description":"Semaglutide is a 31-amino-acid GLP-1 receptor agonist engineered for once-weekly dosing via fatty-acid acylation and amino-acid substitutions that resist DPP-4 degradation. Approved by the FDA for type 2 diabetes (2017) and chronic weight management (2021).","mechanism":"GLP-1 receptor agonism → glucose-dependent insulin secretion, slowed gastric emptying, central appetite suppression.","molecularWeight":4113.6,"molecularFormula":"C187H291N45O59","sequence":null,"cas":"910463-68-2","pubchemCid":56843331,"uniprotId":null,"fdaApproved":true,"url":"https://www.americanpeptide.com/catalog/semaglutide"},{"slug":"tirzepatide","name":"Tirzepatide","aliases":["Mounjaro","Zepbound"],"categories":["metabolic"],"categoryLabels":["Metabolic"],"researchAreas":["Type 2 diabetes","Obesity","Obstructive sleep apnea"],"researchAreaGuides":[{"slug":"weight-loss","label":"Weight Loss & Metabolic Health","url":"https://www.americanpeptide.com/research-areas/weight-loss"},{"slug":"sleep-circadian","label":"Sleep & Circadian Rhythm","url":"https://www.americanpeptide.com/research-areas/sleep-circadian"}],"shortDescription":"Dual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.","description":"Tirzepatide is a 39-amino-acid synthetic peptide acting as a dual agonist at GIP and GLP-1 receptors. Approved by the FDA for type 2 diabetes (2022) and chronic weight management (2023).","mechanism":"Co-activation of GIP + GLP-1 receptors; complementary insulinotropic and satiety effects.","molecularWeight":4813.5,"molecularFormula":"C225H348N48O68","sequence":null,"cas":"2023788-19-2","pubchemCid":166567236,"uniprotId":null,"fdaApproved":true,"url":"https://www.americanpeptide.com/catalog/tirzepatide"},{"slug":"tesamorelin","name":"Tesamorelin","aliases":["Egrifta"],"categories":["growth-hormone","metabolic"],"categoryLabels":["Growth Hormone","Metabolic"],"researchAreas":["Visceral adiposity","HIV-associated lipodystrophy","Cognition"],"researchAreaGuides":[{"slug":"weight-loss","label":"Weight Loss & Metabolic Health","url":"https://www.americanpeptide.com/research-areas/weight-loss"},{"slug":"cognition-neuroprotection","label":"Cognition & Neuroprotection","url":"https://www.americanpeptide.com/research-areas/cognition-neuroprotection"}],"shortDescription":"GHRH analog FDA-approved for HIV-associated lipodystrophy.","description":"Tesamorelin is a stabilized 44-amino-acid GHRH analog approved by the FDA in 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.","mechanism":"GHRH receptor agonism → endogenous GH release.","molecularWeight":5135.9,"molecularFormula":"C221H366N72O67S","sequence":null,"cas":"218949-48-5","pubchemCid":16137828,"uniprotId":null,"fdaApproved":true,"url":"https://www.americanpeptide.com/catalog/tesamorelin"}]}